Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

antibody conjugates

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (26) ADC Linker (713) Antibody-Drug Conjugates (ADCs) (58) Drug-Linker Conjugates for ADC (104) E3 Ligase Ligand-Linker Conjugates (4) Peptide-Drug Conjugates (PDCs) (1) PROTAC-Linker Conjugates for PAC (3) Radionuclide-Drug Conjugates (RDCs) (2) Target Protein Ligand-Linker Conjugates (1) ADC Cytotoxin (80) Akt (1) ALCAM/CD166 (1) Aldehyde Dehydrogenase (ALDH) (1) Amino Acid Derivatives (3) Angiotensin Receptor (2) Antibiotic (12) Antifolate (1) Apoptosis (17) Autophagy (5) Bacterial (17) Beclin1 (1) Beta-lactamase (1) Biochemical Assay Reagents (79) c-Met/HGFR (2) CD19 (1) CD22 (3) CD276/B7-H3 (1) Cytochrome P450 (1) DNA Alkylator/Crosslinker (16) DNA/RNA Synthesis (4) Drug Derivative (1) Drug Intermediate (15) Drug Metabolite (6) EGFR (20) Endogenous Metabolite (7) Epigenetic Reader Domain (7) Estrogen Receptor/ERR (3) Ferroptosis (1) FGFR (2) Fluorescent Dye (18) GLP Receptor (1) Glucocorticoid Receptor (12) Guanylate Cyclase (1) Hedgehog (1) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (2) HIV (2) IGF-1R (1) Influenza Virus (1) Integrin (1) Interleukin Related (2) Isotope-Labeled Compounds (6) JNK (1) Kinesin (1) Liposome (23) MDM-2/p53 (1) Mesothelin (2) Microtubule/Tubulin (56) Mitochondrial Metabolism (1) Mitophagy (1) MMP (1) Mucin (1) Na+/K+ ATPase (1) NAMPT (3) Nectin-4 (3) Notch (2) Nucleoside Antimetabolite/Analog (1) Opioid Receptor (1) Orthopoxvirus (1) Parasite (1) PD-1/PD-L1 (4) Prostaglandin Receptor (1) PROTAC Linkers (206) PROTACs (9) Reactive Oxygen Species (1) Src (1) STING (7) TAM Receptor (4) Thyroid Hormone Receptor (1) TNF Receptor (7) Toll-like Receptor (TLR) (5) Topoisomerase (31) Transmembrane Glycoprotein (1) TROP2 (5) VEGFR (1)
By Research Areas:	Cancer (1025) Cardiovascular Disease (2) Infection (9) Inflammation/Immunology (158) Metabolic Disease (2)
Click Chemistry:	ADC Synthesis (233) TCO (14) DBCO (58) PROTAC Synthesis (53) Azide (82) BCN (21) Tetrazine (31) Alkynes (44)
Oligonucleotides:	Pegylated Lipids (23)

1224

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

136

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

243

Click Chemistry

Oligonucleotides

Targets Recommended: Antibody-Drug Conjugates (ADCs) ADC Antibody PROTAC-Linker Conjugates for PAC ADC Linker Peptide-Drug Conjugates (PDCs) Target Protein Ligand-Linker Conjugates Radionuclide-Drug Conjugates (RDCs) Drug-Linker Conjugates for ADC E3 Ligase Ligand-Linker Conjugates

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132180A

Seco-DUBA	ADC Cytotoxin	Inflammation/Immunology Cancer
Seco-DUBA is a duocarmycin (DUBA) prodrug containing two hydroxyl groups, which can each be used for coupling to an antibody via a linker. Seco-DUBA can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-131955

Fmoc-aminooxy-PEG2-NH2	ADC Linker	Cancer
Fmoc-aminooxy-PEG2-NH2 is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-145620

Zuvotolimod	ADC Linker	Inflammation/Immunology Cancer
Zuvotolimod is a myeloid cell agonist compound-linker for antibody conjugate. Zuvotolimod can be used in the research of cancer and hepatitis .

HY-P99230

Pinatuzumab	Integrin CD22	Cancer
Pinatuzumab is a CD22 monoclonal antibody. Pinatuzumab targets the cell-surface antigen CD22. Pinatuzumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including non-Hodgkin lymphoma (NHL) .

HY-P99233

Camidanlumab HuMax-TAC	Interleukin Related	Cancer
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia .

HY-150075

STING agonist-19	STING	Others
STING agonist-19 can be used to synthesize ISAC (immune-stimulating antibody conjugates) molecule.

HY-P99785

Opucolimab HLX20	PD-1/PD-L1	Cancer
Opucolimab is an *anti-PD-L1* recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .

HY-132158

MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin	Drug-Linker Conjugates for ADC	Cancer
MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (compound 21a), a camptothecin payload, can be conjugated to a monoclonal antibody (mAb) for the synthesis of camptothecin antibody-drug conjugate (ADC) .

HY-160453

MC-Gly-Gly-Phe-Gly-NH-CH2-O-cyclopropane-CH2COOH	Others	Others
MC-Gly-Gly-Phe-Gly-NH-CH2-O-cyclopropane-CH2COOH is a camptothecin derivative. MC-Gly-Gly-Phe-Gly-NH-CH2-O-cyclopropane-CH2COOH can be used for antibody drug conjugate (ADC) .

HY-156516

10NH2-11F-Camptothecin	ADC Cytotoxin Topoisomerase	Cancer
10NH2-11F-Camptothecin is a Camptothecin (HY-16560) analogue that serves as an ADC cytotoxin for the synthesis of antibody-drug conjugates (ADCs). 10NH2-11F-Camptothecin can inhibit tumor growth and is used in cancer research .

HY-156514

MC-GGFG-AM-(10NH2-11F-Camptothecin)	Drug-Linker Conjugates for ADC	Cancer
MC-GGFG-AM-(10NH2-11F-Camptothecin) is an antibody drug conjugates (ADC). MC-GGFG-AM-(10NH2-11F-Camptothecin) binds to the anti-TROp-2 antibody sacituzumab via a hydrolysable pH-sensitive linker and has anti-tumor activity. MC-GGFG-AM-(10NH2-11F-Camptothecin) can be used for cancer research .

HY-156517

7Ethanol-10NH2-11F-Camptothecin	ADC Cytotoxin Topoisomerase	Cancer
7Ethanol-10NH2-11F-Camptothecin is a Camptothecin (HY-16560) analogue that serves as an ADC cytotoxin for the synthesis of antibody-drug conjugates (ADCs). 7Ethanol-10NH2-11F-Camptothecin can inhibit tumor growth and is used in cancer research .

HY-161544

Cholyglycine/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Cholyglycine/BSA is a conjugate of Cholyglycine and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.

HY-161528

T3/OVA	Biochemical Assay Reagents	Inflammation/Immunology
T3/OVA is an antigen-adjuvant conjugate formed by conjugating T3 (thyroxine) with ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161543

DHT/KLH	Biochemical Assay Reagents	Inflammation/Immunology
DHT/KLH is a conjugate of DHT (dihydrotestosterone) and keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt linear epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161561

PROMETON/OVA	Biochemical Assay Reagents	Inflammation/Immunology
PROMETON/OVA is an antigen-adjuvant conjugate formed by the coupling of PROMETON and ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and enhances cross-presentation and the production of antigen-specific T cells.

HY-161587

Chloramphenicol/OVA	Biochemical Assay Reagents	Inflammation/Immunology
Chloramphenicol/OVA is a conjugate of Chloramphenicol (HY-B0239) and Ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation and the production of antigen-specific T cells.

HY-161581

Metronidazole/OVA	Biochemical Assay Reagents	Inflammation/Immunology
Metronidazole/OVA is a conjugate of Metronidazole (HY-B0318) and Ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161583

Marijuana/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Marijuana/BSA is the antigen-adjuvant conjugate of Marijuana and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.

HY-161548

Metronidazole/KLH	Biochemical Assay Reagents	Inflammation/Immunology
Metronidazole/KLH is a conjugate of Metronidazole (HY-B0318) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161529

Angiotensin I/BSA	Angiotensin Receptor	Inflammation/Immunology
Angiotensin I/BSA is an antigen-adjuvant conjugate of Angiotensin I and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161549

Phosphotyrosine/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Phosphotyrosine/BSA is an antigen-adjuvant conjugate formed by coupling Phosphotyrosine with Bovine Serum Albumin (BSA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161553

Biotin/KLH	Biochemical Assay Reagents	Inflammation/Immunology
Biotin/KLH is an antigen-adjuvant conjugate that consists of Biotin and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161531

Diethylstilbestrol/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Diethylstilbestrol/BSA is a conjugate of Diethylstilbestrol (HY-14598) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.

HY-163556

COT/BSA	Biochemical Assay Reagents	Inflammation/Immunology
COT/BSA is the antigen-adjuvant conjugate of COT (cyclooctatetraene) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161542

Isoniazid/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Isoniazid/BSA is an antigen-adjuvant conjugate of Isoniazid (HY-B0329) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161540

Oxytetracycline/OVA	Biochemical Assay Reagents	Inflammation/Immunology
Oxytetracycline/OVA is an antigen-adjuvant conjugate formed by the coupling of Oxytetracycline (HY-B0275) with ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, it enhances the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or destroy the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-163555

BZO/BSA	Biochemical Assay Reagents	Inflammation/Immunology
BZO/BSA is an antigen-adjuvant conjugate formed by the coupling of BZO (benzodiazepine) with bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.

HY-161555

Clenbuterol/KLH	Biochemical Assay Reagents	Inflammation/Immunology
Clenbuterol/KLH is an antigen-adjuvant conjugate of Clenbuterol (HY-B1615) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161554

Clenbuterol/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Clenbuterol/BSA is an antigen-adjuvant conjugate of Clenbuterol (HY-B1615) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161566

DHT/BSA	Biochemical Assay Reagents	Inflammation/Immunology
DHT/BSA is an antigen-adjuvant conjugate formed by the coupling of DHT (dihydrotestosterone) and bovine serum albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161532

Eugenol/OVA	Biochemical Assay Reagents	Inflammation/Immunology
Eugenol/OVA is an antigen-adjuvant conjugate formed by the conjugation of Eugenol (HY-N0337) with Ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt key epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161591

SEM/BSA	Biochemical Assay Reagents	Inflammation/Immunology
SEM/BSA is an antigen-adjuvant conjugate formed by the conjugation of SEM (furanesalin) with bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161594

Furazolidone/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Furazolidone/BSA is the antigen-adjuvant conjugate of Furazolidone (HY-B1336) and bovine serum albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161558

Ractopamine/KLH	Biochemical Assay Reagents	Inflammation/Immunology
Ractopamine/KLH is an antigen-adjuvant conjugate of Ractopamine (HY-113781) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.

HY-161533

Digoxin/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Digoxin/BSA is an antigen-adjuvant conjugate of Digoxin (HY-B1049) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-163553

Metronidazole/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Metronidazole/BSA is an antigen-adjuvant conjugate of Metronidazole (HY-B0318) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.

HY-161590

AHD/BSA	Biochemical Assay Reagents	Inflammation/Immunology
AHD/BSA is the antigen-adjuvant conjugate of AHD (furan-2-carboxylic acid) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy the main epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-163550

5-MethylCytosine/BSA	Biochemical Assay Reagents	Inflammation/Immunology
5-MethylCytosine/BSA is a conjugate of 5-MethylCytosine (HY-W008091) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy key epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161586

Chloramphenicol/BSA	Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase VEGFR Autophagy Apoptosis Beclin1 JNK Akt MMP Biochemical Assay Reagents	Inflammation/Immunology
Chloramphenicol/BSA is the antigen-adjuvant conjugate formed by the coupling of Chloramphenicol (HY-B0239) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161546

Melamine/KLH	Biochemical Assay Reagents	Inflammation/Immunology
Melamine/KLH is an antigen-adjuvant conjugate formed by coupling Melamine (HY-Y1117) with Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161547

Tetracycline/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Tetracycline/BSA is an antigen-adjuvant conjugate formed by the conjugation of Tetracycline (HY-A0107) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it enhances cross-presentation and the generation of antigen-specific T cells.

HY-161535

Oxytetracycline/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Oxytetracycline/BSA is an antigen-adjuvant conjugate formed by the coupling of Oxytetracycline (HY-B0275) with Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.

HY-161580

3-Nitrotyrosine/BSA	Biochemical Assay Reagents	Inflammation/Immunology
3-Nitrotyrosine/BSA is an antigen-adjuvant conjugate formed by the conjugation of 3-Nitrotyrosine with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it enhances cross-presentation and the generation of antigen-specific T cells.

HY-161560

Tacrolimus/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Tacrolimus/BSA is the antigen-adjuvant conjugate formed by the conjugation of Tacrolimus (HY-13756) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161557

Ractopamine/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Ractopamine/BSA is an antigen-adjuvant conjugate formed by the conjugation of Ractopamine (HY-113781) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161534

Sulfadiazine/BSA	Biochemical Assay Reagents	Inflammation/Immunology
Sulfadiazine/BSA is an antigen-adjuvant conjugate formed by the conjugation of Sulfadiazine (HY-B0273) with Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161552

T3/BSA	Biochemical Assay Reagents	Inflammation/Immunology
T3/BSA is an antigen-adjuvant conjugate of T3 (thyroid hormone) and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161559

Sudan I/OVA	Biochemical Assay Reagents	Inflammation/Immunology
Sudan I/OVA is an antigen-adjuvant conjugate formed by coupling Sudan I (HY-D0024) with Ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the main epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

HY-161585

Diethylstilbestrol/KLH	Biochemical Assay Reagents	Inflammation/Immunology
Diethylstilbestrol/KLH is an antigen-adjuvant conjugate formed by the coupling of Diethylstilbestrol (HY-14598) with Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

Cat. No.	Product Name

HY-L023

Toxins for Antibody-Drug Conjugate Research Library

113 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 113 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Cat. No.	Product Name	Type

HY-D1546

Biotin-C2-maleimide	Fluorescent Dyes/Probes
Biotin-C2-maleimide is an antibody conjugate reagent, can bind to many biomolecules without significantly changing the biological activity of the target molecule .

HY-78921AG

Fmoc-3VVD-OH (GMP)	Fluorescent Dye
Fmoc-3VVD-OH (GMP) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-D1112

TFAX 546,SE triethylammonium	Fluorescent Dyes/Probes
TFAX 546,SE triethylammonium, an amine reactive yellow fluorescent dye, can forms bright and photostable conjugates with proteins and antibodies .

HY-78932G

Dap-NE hydrochloride (GMP)	Fluorescent Dye
Dap-NE hydrochloride (GMP) is Dap-NE hydrochloride (HY-78932A) produced by using GMP guidelines. Dap-NE hydrochloride is an intermediate used in the synthesis of antibody-drug conjugates (ADCs) .

HY-D2761

DY-680-NHS ester	Fluorescent Dyes/Probes
DY-680-NHS ester is an amine reactive hydrophilic fluorochrome. It can be conjugated to an antibody with higher D/P ratio without causing fluorescence quenching and conjugate precipitation, and it is widely used in applications including western blotting, microscopy, flow cytometry, and cell-based assays. The spectrum has an excitation of 690nm and emission at 709nm.

HY-15578G

McMMAF (GMP) Maleimidocaproyl monomethylauristatin F (GMP)	Fluorescent Dye
McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .

HY-D2736

BP Light 800 NHS ester	Fluorescent Dyes/Probes
BP Light 800 NHS ester is an amine reactive hydrophilic fluorochrome . It can be conjugated to antibody with higher D/P ratio and widely used applications including western blotting, microscopy, flow cytometry, and cell based assays.

HY-19318G

Fmoc-Val-Cit-PAB (GMP)	Fluorescent Dye
Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.

HY-131833G

Fmoc-Gly-Gly-Phe-OH (GMP)	Fluorescent Dye
Fmoc-Gly-Gly-Phe-OH GMP is a GMP grade Fmoc-Gly-Gly-Phe-OH (HY-131833). Fmoc-Gly-Gly-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-D1111

TFAX 568, SE AFDye 568 NHS Ester	Fluorescent Dyes/Probes
TFAX 568, SE is an orange fluorescent dye and exhibits pH-insensitivity over a very broad range (pH in the 4-10). TFAX 568, SE yields exceptionally bright, photostable conjugates with proteins or antibodies (such as goat anti-mouse IgG) .

HY-126851

Fluorescein-DBCO	Dyes
Fluorescein-DBCO is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Fluorescein-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-D1110

TFAX 594,SE	Fluorescent Dyes/Probes
TFAX 594,SE is a red fluorescent dye and exhibits pH-insensitivity over a very broad range (pH in the 4-10). TFAX 594,SE yields exceptionally bright, photostable conjugates with proteins or antibodies (such as goat anti-mouse IgG) .

HY-D2760

BP Fluor 488 acid	Fluorescent Dyes/Probes
BP Fluor 488 acid is a powerful labeling dye. It will react with the amine group in antibody, proteins, peptides, amino-modified oligos, and other target molecules. The dye has an excitation peak at 499 nm and an emission peak at 520 nm. The conjugates are widely used in microscopy, flow cytometry, and other applications.

HY-123687

DBCO-Sulfo-NHS ester sodium	Dyes
DBCO-Sulfo-NHS ester sodium is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Sulfo-NHS ester (sodium) is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-D1113

TFAX 488,TFP	Fluorescent Dyes/Probes
TFAX 488,TFP is a green fluorescent dye and exhibits pH-insensitivity over a very broad range (pH in the 4-10). TFAX 488,TFP yields exceptionally bright, photostable conjugates with proteins or antibodies (such as goat anti-mouse IgG, streptavidin) .

HY-D1114

TFAX 488,SE dilithium	Fluorescent Dyes/Probes
TFAX 488,SE dilithium is a green fluorescent dye and exhibits pH-insensitivity over a very broad range (pH in the 4-10). TFAX 488,SE dilithium yields exceptionally bright, photostable conjugates with proteins or antibodies (such as goat anti-mouse IgG, streptavidin) .

HY-20336G

Mc-Val-Cit-PABC-PNP (GMP)	Fluorescent Dye
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-D2763

BP Fluor 532 maleimide

Fluorescent Dyes/Probes

BP Fluor 532 maleimide is a photostable, bright yellow-fluorescent dye with pH insensitive emission from pH 4 to pH 10. The excitation of BP Fluor 532 is ideally suited for the frequency-doubled Nd:YAG laser line. BP Fluor 532 dye can be conjugated to a variety of antibodies, peptides, proteins, tracers, and amplification substrates, and is often used for the generation of stable signals in imaging and flow cytometry. Maleimide is the most popular sulfhydryl-reactive group for conjugating the dye to a thiol group on a protein, oligonucleotide thiophosphate, or low molecular weight ligand. The maleimide group specifically and efficiently reacts with reduced thiols (sulfhydryl groups, –SH) at pH 6.5 to 7.5 to form a stable thioether bond. The resulting conjugates exhibit brighter fluorescence and greater photostability than the conjugates of many other spectrally similar fluorophores.

HY-15579BG

MMAF sodium (GMP) Monomethylauristatin F sodium (GMP)	Fluorescent Dye
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-15579G

MMAF (GMP) Monomethylauristatin F (GMP)	Fluorescent Dye
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-78931G

Boc-Dap-NE (GMP)	Fluorescent Dye
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.

HY-D2291

BODIPY TMR NHS ester	Fluorescent Dyes/Probes
BODIPY TMR NHS ester is bright, orange fluorescent dye with Ex/Em of 544/570 nm. The NHS ester (or succinimidyl ester) of BODIPY TMR NHS ester is a popular tool for conjugating the dye to a protein or antibody. NHS esters can be used to label the primary amines (R-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules .

HY-W000423G

DBCO-amine (GMP)	Fluorescent Dye
DBCO-amine GMP is a GMP grade DBCO-amine (HY-W000423). DBCO-amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-amine is a click chemistry reagent, itcontains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-D2745

BP Fluor 594 NHS ester

Fluorescent Dyes/Probes

BP Fluor 594 NHS ester is the most popular tool for modifying proteins or antibodies through the primary amines (Lys), amine-modified oligonucleotides, and other amine-containing biomolecules with BP Fluor 594 label. The labeling occurs most efficiently at pH 7-9 and forms a stable, covalent amide bond. BP Fluor 594 dye can be used for proteins labeling at high molar ratios without significant self-quenching, enabling brighter conjugates and more sensitive detection. BP Fluor 594 is bright, water-soluble, and pH-insensitive from pH 4 to pH 10 red-fluorescent dye with absorption and emission maxima at 590 and 617 nm, respectively. It can be used with the 561 nm and 594 nm laser lines. BP Fluor 594 dye conjugated to a variety of antibodies, peptides, proteins, tracers, and amplification substrates often used for generation of stable signal in imaging and flow cytometry.

HY-D2460

Dextran-CY5.5	Dyes
Dextran-CY5.5 is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673nm and the emission wavelength is 707nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander .

HY-D2738

BP Fluor 532 NHS ester

Fluorescent Dyes/Probes

BP Fluor 532 NHS ester is an amine reactive, yellow-emitting dye routinely used to label proteins or antibodies through primary amines (Lys), amine-modified oligonucleotides, and other amine-containing biomolecules. The labeling occurs most efficiently at pH 7-9 and forms a stable, covalent amide bond. BP Fluor 532 is a bright yellow-fluorescent dye with pH insensitive emission from pH 4 to pH 10. The excitation of BP Fluor 532 is ideally suited for the frequency-doubled Nd:YAG laser line. BP Fluor 532 can be conjugated to a variety of antibodies, peptides, proteins, tracers, and amplification substrates, and is often used for the generation of stable signals in imaging and flow cytometry.

HY-W800680

BP Fluor 488 DBCO

Fluorescent Dyes/Probes

BP Fluor 488 DBCO is a popular labeling dye used in copper-free Click Chemistry reactions. It will react with the azide group in antibody, proteins, peptides, amino-modified oligos, and other target molecules. The dye has an excitation peak at 499 nm and an emission peak at 520 nm. The conjugates are widely used in microscopy, flow cytometry, and other applications. BP Fluor 488 is a pure 5-sulfonated rhodamine molecule and it eliminates the lot-to-lot variation caused by two isomers ratio differences.

HY-W800702

BP Fluor 555 azide

Fluorescent Dyes/Probes

BP Fluor 555 Azide is a water-soluble, bright orange-fluorescent dye with excitation ideally suited for the 532 nm or 555 nm laser lines and visualized with TRITC (tetramethylrhodamine) filter sets. BP Fluor 555 conjugates of antibodies, peptides, and proteins are pH insensitive from pH 4 to pH 10. AF 555 conjugates ideally suited for detection of low abundance targets. BP Fluor 555 Azide can be reacted with terminal alkynes via a copper-catalyzed click reaction (CuAAC). It also reacts with strained cyclooctyne via a copper-free “click chemistry” reaction to form a stable triazole and does not require Cu-catalyst or elevated temperatures. The brightness and photostability of this dye are best suited to direct imaging of low-abundance targets.

HY-131990G

MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (GMP)	Fluorescent Dye
MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH GMP is a GMP grade MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (HY-131990). MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-W800701

BP Fluor 546 DBCO

Fluorescent Dyes/Probes

BP Fluor 546 DBCO is an azide-reactive probe that can be used for imaging azide-tagged biomolecules via a copper-free click reaction. The DBCO moiety reacts with azides to form a stable triazole and does not require a Cu-catalyst or elevated temperatures. In applications where the presence of copper is a concern, BP Fluor 546 DBCO is an ideal alternative to copper-requiring fluorescent alkynes. BP Fluor 546 is a water-soluble, pH-insensitive (from pH 4-10), orange-fluorescent dye with absorption and emission maxima at 554 and 570 nm, respectively. It can be used with the 488 nm and 532 nm laser lines. BP Fluor 546 dye conjugates to a variety of antibodies, peptides, proteins, tracers, and amplification substrates, which are often used for generating stable signals in imaging and flow cytometry.

Cat. No.	Product Name	Target	Research Area

HY-136432

Mc-Gly-Gly-Phe-Gly-PAB-OH Mc-GGFG-PAB-OH	ADC Linker	Cancer
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

HY-P1449

Boc-Gly-Gly-Phe-Gly-OH	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-136432A

Mc-Gly-Gly-Phe-Gly-PAB-OH TFA Mc-GGFG-PAB-OH TFA	ADC Linker	Cancer
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) TFA is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

HY-P1449A

Boc-Gly-Gly-Phe-Gly-OH TFA	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-P5271

Influenza hemagglutinin (HA) epitope	Peptides	Others
Influenza hemagglutinin (HA) epitope is a polypeptide. Influenza hemagglutinin (HA) epitope is conjugated to keyhole limpet hemocyanin to generate anti-HA polyclonal antibodies following immunization of rabbits .

HY-P4166

Ac-{Gly(N-me)}-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar	Peptides	Cancer
Ac-{Gly(N-me)}-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar is a decapeptide. Ac-{Gly(N-me)}-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar-Sar can be used to preparation of antibody-drug conjugate .

HY-P10250

HIV gp120 (308-331)	HIV	Inflammation/Immunology
HIV gp120 308-331 is HIV antigen fragments, that conjugates with keyhole limpet hemocyanin (KLH) and generates specific anti-HIV antibody .

HY-P10252

HIV gp120 (421-438)	HIV	Inflammation/Immunology
HIV gp120 421-438 is HIV antigen fragments, that conjugates with keyhole limpet hemocyanin (KLH) and generates specific anti-HIV antibody .

HY-P10870

Pep1-DNP conjugate 9	Peptide-Drug Conjugates (PDCs) FGFR Apoptosis	Cancer
Pep1-DNP conjugate 9 is a functionalized peptide which is composed of the DNP-Hapten and the FGFR1 binding peptide. Pep1-DNP conjugate 9 exhibits good affinity to FGFR1 with K_D of 5.01 μM. Pep1-DNP conjugate 9 recruits anti-DNP antibodies to the surface of FGFR1-positive cells, inhibits the FGF2-induced proliferation in rat skeletal myoblast cells, and induces apoptosis. Pep1-DNP conjugate 9 exhibits antitumor efficacy in mouse models .

HY-W729138

Fmoc-D-homoArg(Et)2-OH hydrochloride	ADC Linker	Others
Fmoc-D-homoArg(Et)2-OH (hydrochloride) is a Fmoc-protected derivative of D-Homoarginine (HArg) that renders peptides and proteins resistant to proteolysis by trypsin. Fmoc-D-homoArg(Et)2-OH (hydrochloride) can be used as a cleavable ADC linker to synthesize antibody-drug conjugates (ADCs) .

Cat. No.	Product Name	Target	Research Area

HY-P99230

Pinatuzumab	Integrin CD22	Cancer
Pinatuzumab is a CD22 monoclonal antibody. Pinatuzumab targets the cell-surface antigen CD22. Pinatuzumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including non-Hodgkin lymphoma (NHL) .

HY-P99233

Camidanlumab HuMax-TAC	Interleukin Related	Cancer
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia .

HY-P99360

Enapotamab Anti-AXL/UFO Reference antibody (enapotamab)	TAM Receptor	Cancer
Enapotamab is an *anti-AXL/UFO* reference antibody. Enapotamab can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates .

HY-P99956

Zilovertamab vedotin VLS-101; MK-2140	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer .

HY-P99453

Azintuxizumab	ADC Antibody	Cancer
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .

HY-P991041

Anti-SEZ6 Antibody (SC17)	ADC Antibody	Cancer
Anti-SEZ6 Antibody (SC17) is an anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011 .

HY-141607

Indatuximab ravtansine BT-062; nBT062-DM4	Antibody-Drug Conjugates (ADCs) Bacterial	Cancer
Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .

HY-P99718

Lupartumab BAY 1112623	ADC Antibody	Cancer
Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980 .

HY-P99785

Opucolimab HLX20	PD-1/PD-L1	Cancer
Opucolimab is an *anti-PD-L1* recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .

HY-145627

Ozuriftamab vedotin BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .

HY-P991081

VHH antibody (His tag), Isotype Control	Hedgehog	Others
VHH antibody (His tag), Isotype Control is a His-conjugated antibody used as a negative control in VHH antibody (His tag) staining applications. VHH antibody (His tag), Isotype Control has the same immunoglobulin class and subclass as the VHH antibody (His tag) which is used in the experiment but lack affinity to the protein of interest .

HY-P99016

Enfortumab	ADC Antibody Nectin-4	Cancer
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .

HY-P99352

Anetumab Anti-MSLN antibody	Mesothelin	Cancer
Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor .

HY-141606

Anetumab ravtansine BAY 94-9343	Microtubule/Tubulin Antibody-Drug Conjugates (ADCs)	Cancer
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent **antibody-drug conjugate (ADC) to target maytansinoid tubulin*. Anetumab ravtansine consists of a human anti-mesothelin antibody* conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .

HY-P99285

Denintuzumab 1 Publications Verification hBU 12	ADC Antibody CD19	Others
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .

HY-P99712

Lonigutamab hz208F2-4	IGF-1R ADC Antibody	Cancer
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody that can be used for the synthesis of antibody–agent conjugates (ADC) .

HY-P99854

Disitamab RC48-0	EGFR ADC Antibody	Cancer
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)) .

HY-P99612

Farletuzumab ecteribulin MORAb-202	Antibody-Drug Conjugates (ADCs)	Cancer
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.

HY-P99788

Praluzatamab	ADC Antibody ALCAM/CD166	Cancer
Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug *conjugates*). Praluzatamab can be used for research of cancers .

HY-P99101

Vobramitamab AEX-4089	ADC Antibody	Cancer
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .

HY-P99151

Brentuximab	ADC Antibody TNF Receptor	Cancer
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC₅₀ of 10 nM against human CD30+ cancer cells .

HY-P99334

Vorsetuzumab mafodotin Anti-Human CD70 Recombinant antibody; SGN-75	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity .

HY-P99264

Inotuzumab Humanized Anti-CD22 Recombinant antibody	ADC Antibody CD22 Apoptosis	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR	Cancer
Aprutumab ixadotin (BAY 1187982) is the first **antibody-drug conjugate (ADC) to target FGFR2** and the first to use Auristatin-based payload .

HY-P99043

Rovalpituzumab	Notch	Cancer
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .

HY-P99967

Cantuzumab	ADC Antibody	Cancer
Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .

HY-P9980A

Belantamab (FUT-8 KO)	ADC Antibody TNF Receptor	Cancer
Belantamab (FUT-8 KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT-8 KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .

HY-P990027

Izeltabart	ADC Antibody	Cancer
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a *Drug-Linker Conjugates* for ADC*), to synthesize IMGC936 (Antibody-Drug Conjugates* (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .

HY-P99733

Mipasetamab	ADC Antibody TAM Receptor	Cancer
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .

HY-P99016B

Enfortumab vedotin-ejfv (solution)	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable maleimidocaproylvaline-citrulline linker (SGD-1006). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-P99740

Mirzotamab	CD276/B7-H3 ADC Antibody	Cancer
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .

HY-P99970

Lifastuzumab	ADC Antibody	Others
Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity .

HY-P99685

Laprituximab emtansine IMGN-289; J2898A-SMCC-DM1	EGFR Antibody-Drug Conjugates (ADCs)	Cancer
Laprituximab emtansine (IMGN-289) is an immunotoxin targeting HER1. Laprituximab emtansine is an EGFR antibody-drug conjugate (ADC) consisting of the J2898A antibody, DM1 (anti-microtubule agent) and the SMCC thioether linker. Laprituximab emtansine can be used for cancer research .

HY-P990049

Becotatug JMT-101	EGFR	Cancer
Becotatug (JMT-101) is an IgG1 antibody targeting EGFR that can also be conjugated to Afatinib (HY-10261) and Osimertinib (HY-15772) as a synthetic ADC .

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-P99454

Azintuxizumab vedotin ABBV-838	Antibody-Drug Conjugates (ADCs)	Cancer
Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells .

HY-P99234

Pivekimab	Interleukin Related ADC Antibody	Cancer
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .

HY-132253

Polatuzumab vedotin	Antibody-Drug Conjugates (ADCs)	Cancer
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .

HY-P99682

Ladiratuzumab hLIV22	Inhibitory Antibodies	Cancer
Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) .

HY-P99971

Gemtuzumab	ADC Antibody	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia .

HY-P99656

Iladatuzumab MCDS0593A	ADC Antibody	Cancer
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .

HY-P99813

Patritumab deruxtecan HER3-DXd; U3-1402	Antibody-Drug Conjugates (ADCs)	Cancer
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .

HY-P99238

Rolinsatamab	ADC Antibody	Inflammation/Immunology Cancer
Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an **antibody-drug conjugate**, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (S239C). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (S239C) .

HY-164153

ADC Control Human IgG1-vcMMAE	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .

HY-P99500

Cetuximab sarotalocan RM-1929; Cetuximab-IRDye-700DX	EGFR	Cancer
Cetuximab sarotalocan (RM-1929) is an IRdye700DX (near-infrared photosensitizing dye) conjugate of Cetuximab (anti-EGFR monoclonal antibody). Cetuximab sarotalocan can be used for head and neck cancers research .

HY-P99921

Enapotamab vedotin HuMax-AXL-ADC	Antibody-Drug Conjugates (ADCs) EGFR TAM Receptor	Cancer
Enapotamab vedotin is an AXL-targeted antibody-drug conjugate with inhibitory potential against non-small cell lung cancer (NSCLC). Enapotamab vedotin also targets the PDX models resistant to EGFR mutations and EGFR inhibitor (osimertinib) .

HY-P99630

Gancotamab MM-302	EGFR	Cancer
Gancotamab (MM-302) is a HER2-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .

HY-P99843

Datopotamab	TROP2 ADC Antibody	Cancer
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .

HY-P99881

Rolinsatamab talirine ABBV 176	Drug-Linker Conjugates for ADC	Cancer
Rolinsatamab talirine (ABBV 176) is an antibody-drug conjugate (ADC) targeting prolactin receptor (PRLR). Rolinsatamab talirine consists of rolinsatamab (HY-P99238), an enzymatically cleavable peptide linker, and SGD-1882 (HY-101127) .

HY-164152

ADC Control Human IgG1-Deruxtecan (DAR 4)	Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W034595

Eicosanedioic acid	Microorganisms Source classification	ADC Linker PROTAC Linkers
Eicosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Eicosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis

HY-117371

Hemiasterlin (-)-Hemiasterlin; Milnamide B	Alkaloids Structural Classification Classification of Application Fields Animals Marine natural products Sponge Disease Research Fields Indole Alkaloids Cancer	ADC Cytotoxin
Hemiasterlin ((-)-Hemiasterlin) is an antimitotic marine natural product with potent anticancer effcts. Hemiasterlin can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .

HY-W034918

Docosanedioic acid	Structural Classification other families Classification of Application Fields Ketones, Aldehydes, Acids Source classification Plants Disease Research Fields Cancer	ADC Linker PROTAC Linkers
Docosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Docosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.

HY-W007324

Maleimide	Alkaloids Microorganisms Pyrrole Alkaloids Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Cancer	ADC Linker Biochemical Assay Reagents
Maleimide can be used for production of antibody-drug conjugate (ADC) which is used in cancer research. Maleimide also be leveraged for the preparation of fluorogenic probe, which is mainly used for the specific detection of thiol analytes .

Cat. No.	Product Name	Chemical Structure

HY-12454S

DM4-d6
DM4-d₆ is deuterium labeled DM4. DM4 is is an antitubulin agent that inhibit cell division. DM4 can be used in the preparation of antibody agent conjugate.

HY-15583S

Auristatin F-d8
Auristatin F-d₈ is deuterium labeled Auristatin F (HY-15583). Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .

HY-145397S

(4-NH2)-Exatecan-d5
(4-NH2)-Exatecan-d5 is a deuterated labeled (4-NH2)-Exatecan . (4-NH2)-Exatecan (compound A), a topoisomerase inhibitor, is a derivative of Exatecan. (4-NH2)-Exatecan can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-161022S1

FL118-C3-O-C-amide-C-NH2-d5 formate
FL118-C3-O-C-amide-C-NH2-d5 formate is a deuterium labeled FL118-C3-O-C-amide-C-NH2 formate. FL118-C3-O-C-amide-C-NH2 formate is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-19792S1

Mertansine-d9
Mertansine-d₉ (DM1-d₉) is deuterium labeled Mertansine. Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-114816S

N-butyryl-L-Homoserine lactone-d5

N-butyryl-L-Homoserine lactone-d₅ is the deuterium labeled N-Butanoyl-L-homoserine lactone. N-Butanoyl-L-homoserine lactone (C4-HSL) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Butanoyl-L-homoserine lactone has antibacterial activity and is used in antibacterial biofilm[1]. N-Butanoyl-L-homoserine lactone aptamers blocks qurom sensing and inhibits biofilm formation in Pseudomonas aeruginosa[2][3].

Cat. No.	Product Name		Classification

HY-144013H

18:0 mPEG5000 PE ammonium DSPE-mPEG5000 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium		Pegylated Lipids
18:0 mPEG5000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012A

DPPE-PEG350 16:0 PEG350 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium		Pegylated Lipids
DPPE-PEG350 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012B

DPPE-PEG550 16:0 PEG550 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium		Pegylated Lipids
DPPE-PEG550 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155926

DMPE-PEG750 14:0 PEG750 PE; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium		Pegylated Lipids
DMPE-PEG750 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155931

18:1 PEG550 PE DOPE-PEG550; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium		Pegylated Lipids
18:1 PEG550 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013B

18:0 mPEG550 PE ammonium DSPE-mPEG550 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium		Pegylated Lipids
18:0 mPEG550 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012C

DPPE-PEG750 16:0 PEG750 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium		Pegylated Lipids
DPPE-PEG750 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155924

DMPE-PEG350 14:0 PEG350 PE; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium		Pegylated Lipids
DMPE-PEG350 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155927

DMPE-PEG1000 14:0 PEG1000 PE; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium		Pegylated Lipids
DMPE-PEG1000 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012E

DPPE-PEG3000 16:0 PEG3000 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium		Pegylated Lipids
DPPE-PEG3000 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013A

18:0 mPEG350 PE ammonium DSPE-mPEG350 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium		Pegylated Lipids
18:0 mPEG350 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013D

18:0 mPEG1000 PE ammonium DSPE-mPEG1000 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium		Pegylated Lipids
18:0 mPEG1000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155934

18:1 PEG5000 PE DOPE-PEG5000; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium		Pegylated Lipids
18:1 PEG5000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012D

DPPE-PEG1000 16:0 PEG1000 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium		Pegylated Lipids
DPPE-PEG1000 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155933

18:1 PEG3000 PE DOPE-PEG3000; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium		Pegylated Lipids
18:1 PEG3000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155932

18:1 PEG1000 PE DOPE-PEG1000; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium		Pegylated Lipids
18:1 PEG1000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012H

DPPE-PEG5000 16:0 PEG5000 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium		Pegylated Lipids
DPPE-PEG5000 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155925

DMPE-PEG550 14:0 PEG550 PE; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium		Pegylated Lipids
DMPE-PEG550 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013E

18:0 mPEG3000 PE ammonium DSPE-mPEG3000 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium		Pegylated Lipids
18:0 mPEG3000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155930

18:1 PEG350 PE DOPE-PEG350; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium		Pegylated Lipids
18:1 PEG350 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013C

18:0 mPEG750 PE ammonium DSPE-mPEG750 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium		Pegylated Lipids
18:0 mPEG750 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155929

DMPE-PEG5000 14:0 PEG5000 PE; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium		Pegylated Lipids
DMPE-PEG5000 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155928

DMPE-PEG3000 14:0 PEG3000 PE; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium		Pegylated Lipids
DMPE-PEG3000 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

antibody conjugates

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products